WANY
KURA icon

Wealthspire Advisors (New York)’s Kura Oncology KURA Stock Holding History

Wealthspire Advisors (New York)’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$89 – 2035
2025
Q3 		$89 Buy
+10
New +$71 ﹤0.01% 3002

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Wealthspire Advisors (New York)'s KURA Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Kura Oncology (KURA) in Q4 2025, closing a stake of 10 shares — an estimated $89 sold.

Wealthspire Advisors (New York) first reported a position in KURA in Q3 2025 and held it in 1 quarter. The position peaked at $89 in Q3 2025. 215 funds tracked by Wall St. Rank hold KURA as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Kura Oncology position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 10 Kura Oncology shares in Q4 2025, an estimated $89.
  • Wealthspire Advisors (New York) first reported a position in Kura Oncology in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Kura Oncology position peaked at $89 in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.